MenAfriVac

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
05101520112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND In preparation for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for the African… (More)
Is this relevant?
2016
2016
BACKGROUND Neisseria meningitidis colonizes humans and transmits mainly by asymptomatic carriage. We sought to determine the… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
BACKGROUND The introduction of MenAfriVac in campaigns targeting people aged 1-29 years across the African meningitis belt has… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
BACKGROUND Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine… (More)
  • figure 1
Is this relevant?
2015
2015
BACKGROUND A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed to… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2015
Review
2015
BACKGROUND The Meningitis Vaccine Project (MVP) was established to address epidemic meningitis as a public health problem in sub… (More)
  • figure 1
Is this relevant?
2014
2014
BACKGROUND To ensure vaccines safety, given the weaknesses of the national pharmacovigilance system in Cameroon, there is a need… (More)
Is this relevant?
2014
2014
INTRODUCTION An estimated one hundred million African meningitis belt residents have received MenAfriVac(®)meningococcal… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
INTRODUCTION MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A, the major cause of meningitis… (More)
Is this relevant?